Accelerate Diagnostics, Inc.
AXDX

$41.07 M
Marketcap
$1.64
Share price
Country
$-0.03
Change (1 day)
$5.23
Year High
$0.73
Year Low
Categories

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

marketcap

P/B ratio for Accelerate Diagnostics, Inc. (AXDX)

P/B ratio as of 2023: -2.46

According to Accelerate Diagnostics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -2.46. At the end of 2022 the company had a P/B ratio of -2.62.

P/B ratio history for Accelerate Diagnostics, Inc. from 1996 to 2023

P/B ratio at the end of each year

Year P/B ratio
2023 -2.46
2022 -2.62
2021 -9.19
2020 -6.76
2019 -124.83
2018 10.92
2017 11.81
2016 13.67
2015 7.27
2014 12.69
2013 11.05
2012 2.75
2011 8.52
2010 1.84
2009 7.09
2008 10.08
2007 4.80
2006 3.53
2005 3.29
2004 1.99
2003 2.73
2002 0.46
2001 1.14
2000 0.39
1999 1.38
1998 3.08
1997 10.01
1996 2.89